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the amyloid-beta (Ab) peptide constitutes an interesting research avenue that involves interactions
within a complex mixture of Ab alloforms and other disease-modifying factors. Here, we explore
the potential of an ecosystem paradigm as a novel way to consider AD and Ab dynamics in particular.
We discuss the example that the complexity of the Ab network not only exhibits interesting parallels
with the functioning of complex systems such as ecosystems but that this analogy can also provide
novel insights into the neurobiological phenomena in AD and serve as a communication tool. We pro-
pose that combining network medicine with general ecosystem management principles could be a
new and holistic approach to understand AD pathology and design novel therapies.
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Alzheimer’s disease (AD), the most common form of
dementia, affects the human brain and causes severe
memory loss and behavioral changes. Despite some
promising drug candidates targeting AD, clinical trials,
however, remain unsuccessful due to a lack of efficacythor. Tel.: 132-2-6291924; Fax: 132-2-6291963.
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commons.org/licenses/by-nc-nd/4.0/).or safety issues [1]. Current treatment is still limited to
the alleviation of disease symptoms without the arrest or
reversion of the underlying disorder. This lack of success
reflects the general failure to fully comprehend the neuro-
biology of AD and the underlying pathogenesis. As
multiple biochemical pathways are affected in AD, it is
conceivable that targeting only one disease pathway might
have an overall negligible effect as other disease mecha-
nisms and pathways could still play a dominant role.
The main molecular hallmarks of the disease are the
formation of amyloid plaques and neurofibrillary tanglesimer’s Association. This is an open access article under the CC BY-NC-ND
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and neuronal cell death [2]. In addition to the deposition
of the amyloid-beta (Ab) peptide and the hyperphosphor-
ylation of tau, AD pathology also includes neuronal
degeneration, an impaired microvasculature, a dysfunc-
tional blood brain barrier, neuroinflammation, mitochon-
drial deterioration, oxidative stress, cytoskeleton
disintegration, and epigenetic changes [3]. Although the
amyloid cascade hypothesis is still influential to explain
the pathophysiology of AD, alternative views consider
tau as the main driving force of AD [4] or deem that
several pathogenic features of AD can be interpreted as
amyloid-independent alterations of synaptic plasticity,
endolysosomal trafficking, cell cycle regulation, and
neuronal survival [5]. Another hypothesis suggests that
AD results from accelerated neural and cognitive decline
in the vulnerable, aged brain due to microvascular failure
and decreased angiogenesis [6]. In most cases, AD thus
results from the interplay between certain susceptibility
genes, environmental factors, and lifestyle contributors
[7]. Therefore, it is essential that drug development stra-
tegies not only address the complexity of a single disease
component (e.g. Ab, tau, neuroinflammation.) but also
address the multifactorial nature of this disease and the
dynamics of the various interacting disease-contributing
factors [8]. Developing new therapeutic strategies is
indispensable as AD incidence is predicted to nearly
triple by 2050 if no cure becomes available [9].
In an effort to approach AD from a different angle, we
postulate that a similar complexity can be observed in
complex systems such as ecosystems, which can be defined
as networks of interactions among species and their envi-
ronment [10]. In ecosystems, the relative abundance of
the composing species is continuously molded by environ-
mental conditions affecting the relative population growth
of species, priority effects (i.e. order of emergence or
arrival of species [11]), and biotic interactions among
species [12]. As a result, community structure may change
over time, and the resulting trajectories may lead to
different equilibria or oscillations [13] that, in turn, will
determine the functions and services provided by the
system (e.g. productivity, efficiency of biochemical cycles,
and resistance against invasive species). Similarly, the tem-
poral dynamics in the composition of disease factors may
also be governed by inter- and intra-molecular interactions,
changes in environmental conditions, and priority effects
[14]. The end point of the evolution of a complex system
may be deterministic (e.g. the formation of plaques in
AD, the eutrophication of a lake, ecological succession
toward a climax forest after a fire.), but the route to get
there may not be. For instance, some elderly people retain
a normal cognitive function despite having a high amyloid
load in their brain, whereas others show severe cognitive
decline with little Ab deposition [15]. There could also
be different end points, some of which may be preferable
over others (e.g. turbid vs. clear water states in lakes, treesavannah vs. grass savannah). Finally, the stochastic nature
of community trajectories should be investigated as order
of arrival (priority effects) or small initial deviations
followed by positive feedbacks could reduce the predict-
ability of responses [13]. Based on these insights from
ecosystem ecology, we postulate that a better knowledge
of the interplay between the drivers that determine
variation in the temporal trajectories of disease-
contributing factors, by minimizing or avoiding trajectories
that are associated with toxicity and neurodegeneration,
may render AD treatment more effective.
This perspective article explores the parallel that exists
between the complexity of the molecular interactions
within AD and the complex architecture of direct and
indirect interactions in ecosystems (Fig. 1). We propose
that insights from ecology, community assembly theory,
and ecosystem management principles, in particular, (Box
1) might provide novel useful insights into AD pathogen-
esis and could serve as a guiding principle for innovative
therapy design. Moreover, this framework provides an
additional opportunity to establish a dialog between
researchers, medical experts, industrial partners, and the
lay public (patients and caregivers) using more familiar
observable natural events as proxies for molecular and
cellular events in AD. The power of such a communication
strategy is nicely illustrated with the cover image of the
November 2014 issue of this Journal, which depicts the
North American woodpecker. As described in the editorial,
the “woodpecker model” provides a comparative mind-set
to gain more insight into the link between traumatic brain
injuries and the subsequent development of
neurodegenerative diseases [17].2. Comparison of Ab behavior in AD with general
ecosystem principles
As the idea originated from the viewpoint of bench
scientists investigating the role of Ab in AD, we have
used the Ab peptide as an example to showcase some of
the commonalities between AD complexity and ecological
principles. The main driving force for writing this perspec-
tive is the emerging picture of increasing complexity for
Ab aggregation, whereby Ab dynamics at different levels
play a crucial role in AD [14]. Yet, that picture remains
incomplete as all therapeutic intervention strategies that
target Ab production, accumulation, or clearance have
failed hitherto and there is still no means to cure or even
halt the disease [3]. This fact alone provides strong support
for the development of a combination therapy to tackle
AD. Thus, this ecosystem paradigm should not be limited
to Ab as a disease-contributing factor, but similar analogies
can be envisioned with other disease components (e.g. tau,
neuroinflammation.) that can be combined in more
complex models.
Ecosystems can be perceived at different levels in the
context of AD: the brain, the extracellular space, or
Fig. 1. A schematic comparison of the Ab-flux in the context of Alzheimer’s disease and the carbon-flux in an example of an ecosystem. The Ab peptide is
considered as a central player in AD and can be depicted in a network of many interacting molecules. Influences of the environment and an individual’s lifestyle
can contribute to disease outcome. The commonalities between the Ab network and the complexity of an ecosystem reveal a conceptual framework that can lead
to the development of more efficient AD therapeutic strategies. This illustration is an oversimplification to highlight the ecosystem paradigm and does not reflect
the physiological roles of APP, Ab, and the secretases. Abbreviations: Ab, amyloid-beta; AD, Alzheimer’s disease.
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Box 1
Use of the term “Ecosystem management”
We define ecosystemmanagement as the management
of abiotic factors and/or biotic interactions in a natural
environment of interacting species to maximize
ecosystem services. Ecosystem services are the direct
and indirect contributions of ecosystems to human
well-being [16]. When natural resource management is
applied to the whole ecosystem, rather than a single
species, it is termed ecosystem management (Fig. 2A).
Key aspects of ecosystem management include
 Integration of ecological, social, and economic
goals and recognition of humans as key components
of the ecosystem.
 Accounting for the complexity of natural processes
and social systems and using an adaptive manage-
ment approach in the face of resulting uncertainties
by carefully monitoring various parameters.
 Incorporating understanding of ecosystem pro-
cesses and how ecosystems respond to environ-
mental perturbations.
 Emphasizing the protection and restoration of
ecosystem structure, function, and key processes.
The fundamental objective of ecosystem management
is long-term stability. In this context, manipulative ex-
periments that aim to push an ecosystem into another
state and sound ecological models that incorporate mul-
tiple stable states and alternative trajectories to capture
the complex dynamics of ecosystems play an important
role to achieve this goal [10].
Box 2
Use of the term “Ab alloform”
An Ab alloform is defined as a distinct form of the Ab
peptide that is commonly treated as a single kind of pep-
tide species. This includes the different Ab peptide length
variants and posttranslational side-chain modifications.
Ab peptides are generated from the transmembrane am-
yloid precursor protein (APP) by sequential cleavages by
b-secretase and g-secretase. The b-secretase cleavage
site is fixed, but imprecise g-secretase cleavage at the C-
terminal end results in Ab peptides of various lengths
ranging from 37 to 49 amino acids. The most abundant
forms are Ab1–40, composed of 40 amino acids, and Ab1–
42, that is C-terminally extended by two hydrophobic
residues, making this alloform more aggregation prone.
Furthermore, Ab peptides can undergo posttranslational
side-chain modifications including racemization, isom-
erization, phosphorylation, oxidation, nonenzymatic
glycation and pyroglutamylation [14]. Mass spectrom-
etry (in combination with immunoprecipitation) is the
most frequently used method to gain insight into the
composition of the Ab peptide pool in the brain or CSF.
Ab alloform mixtures behave in a more complex manner
than when studied in isolation in terms of aggregation
behavior, dynamics, and toxic properties [23–25].
However, the complexity of the “Ab system” is still a
largely unexplored field of study, hampering a good
understanding of the neurobiology of AD. Therefore,
interactions between Ab alloforms require further
investigation and should be considered when designing
new therapeutic strategies.
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Similarly, in nature, one could consider e.g. a forest, an
individual tree, or even a leaf as ecosystem boundaries.
The choice of ecosystem boundaries will define the subset
of “species” and interactions to include in the analysis,
although the boundaries are not necessarily absolute. In
this example, the human brain can be considered as an
ecosystem (Fig. 1).
There is a flow of Ab throughout the life span of an
individual. The production of Ab is a physiological process
that occurs in neuronal cells and is essential for normal
synaptic activity [18]. There is a tight regulation of Ab pro-
duction with its degradation that occurs via receptor-
mediated transfer across the blood brain barrier, enzymatic
proteolysis (e.g. insulin-degrading enzyme, neprilysin)
[19], or the glymphatic drainage system [20]. Similarly,
biogeochemical cycles that move chemical substances
(e.g. water, carbon-rich compounds, and so forth) through
the biotic and abiotic compartments of an ecosystem are crit-
ical for life. These molecules may be recycled or accumu-
lated in a sink/reservoir, such as different ecosystem
compartments species, tissues, or biomass [10]. Similarly
to an imbalance between Ab production and clearance thatcan result in Ab accumulation in plaques throughout the
brain [21], aberrations in biogeochemical cycles can alter
the structure and functioning of natural and managed
ecosystems [22].
The Ab monomeric peptide pool in the brain contains
multiple different Ab variants, including different peptide
lengths and side-chain modifications. We will collectively
refer to all these Ab variants as Ab alloforms (Box 2). In
addition to Ab species’ diversity described previously,
several Ab mutants have been linked to the familial
type of AD that occurs at early age, defined as before
the age of 65 [26]. Taking Ab peptide pool diversity
into account, a parallel can be seen with variation in the
relative abundance of species’ ecological communities
or in the relative abundance of genotypes in populations.
In both cases, interactions occur between entities, that
differ in the effects they have on overall ecosystem
functioning.
The in vivo Ab peptide pool is a complex mixture of
Ab species influencing one another, similar to the interac-
tions that occur between species in an ecosystem [10]. It
has now been recognized that the composition of this
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inent role in disease outcome as different Ab alloforms
can influence each other’s aggregation behavior and toxic
properties [23–25]. For example, shifts in the Ab1–42:Ab1–
40 ratio can modulate the formation of neurotoxic
oligomers [23]. Minor traces of Ab1–38 can render Ab1–
40 toxic to a neuroblastoma cell line while exerting a
cytoprotective effect on Ab1–42 [25]. Moreover, the inter-
play between different Ab aggregation states must also be
considered, as they exist in a dynamical equilibrium, and
it has been suggested that the ongoing aggregation, rather
than a specific toxic entity, is responsible for Ab-related
toxicity [27]. The inherent dynamical character of the
Ab system [14] is in agreement with the fact that ecosys-
tems are dynamical entities [10].
Mounting evidence shows that environmental factors
influence AD and Ab properties. Air pollution has been
reported to accelerate Ab accumulation and induce oxidative
stress [28]. Metals (Cu, Zn, Fe, and Al) colocalize with Ab
plaques and induce Ab toxicity through enhanced Ab aggre-
gation and production of reactive oxygen species [29]. Stress
or exposure to environmental toxins can also induce
epigenetic changes related to memory and learning. In this
regard, exposure to lead early in life has been demonstrated
to upregulate genes involved in AD late in life in primates,
through mechanisms involving DNA methylation and his-
tone acetylation [30]. Recent postmortem brain tissue anal-
ysis have yielded the first evidence that the lifestyle changes
that increase AD risk may be taking effect through epige-
netic changes of gene function [31,32]. However, more
research is required to reveal if those epigenetic changes
play a causal role in AD or occur as a result of it.
Interestingly, as epigenetic changes are potentially
reversible, they may provide targets for the development
of new therapies as suggested for AD associated with
Down syndrome [33]. Exposure to synthetic pesticides is
also associated with increased risk of late-onset AD [34],
although these compounds have profound effects in natural
ecosystems [35]. Similarly, environmental stressors can
change the temporal trajectories of ecosystems resulting in
unfavorable ecosystem states such as turbid ponds (Fig. 2),
bleached coral reefs, or nutrient-depleted soils [37]. In addi-
tion, in response to environmental stimuli, epigenetic
changes may occur that can affect important ecological
phenomena (e.g. response to invasive species, disease sus-
ceptibility.). Moreover, epigenetics may contribute to the
process of adaptation [38]. Adaptability and inertia (i.e.
resistance to adapt) can help an ecosystem to respond to
environmental change to a certain extent. Additionally,
numeric advantages e.g. via priority effects can inhibit or
slow down ecosystem responses to environmental change.
Human lifestyle has been suggested to be associated with
AD development and Ab properties. Several food compo-
nents have been proposed to be potent inhibitors of Ab
aggregation or to act as anti-inflammatory molecules or
antioxidants [39]. Prolonged cognitive and physical exercisehas been shown to have a positive effect on the rate of cogni-
tive decline [40]. In contrast, severe brain injury [41] and
type II diabetes [42] are important risk factors for AD devel-
opment. Similarly, environmental change (including human
impact) is a main driver of ecosystem trajectories [10]. The
behavior of humans can affect ecosystems in numerous
ways, e.g. by pollution, deforestation, and over-fishing but
also by replanting and sustainable energy usage. Certain
discrepancies should, however, be noted. In the case of
AD, lifestyle affects the state of the individual itself, whereas
in the case of an ecosystem, humans impact the entire system
around them, which ultimately may impact the state of the
individual (e.g. air pollution may cause asthma).
Temporal changes in the brain associated with aging are
the most important risk factors for AD development (tempo-
ral heterogeneity). Aging is associated with defective protein
synthesis, with less efficient quality control mechanisms,
and with cumulative oxidative damage. However, the contri-
bution of aging to AD is highly complex and still not yet
fully understood [43]. Likewise, ecosystems are often not
stable over time and may evolve from one equilibrium to
another or experience regular cycles. This process is driven
by birth and death rates (demography), colonization
dynamics, extinction, and priority effects. The latter implies
that the presence of some species may inhibit or facilitate the
settlement of others, resulting in ecological succession [13].
These phenomena can compare in AD to the synthesis and
clearance rates of Ab, the distribution pattern of Ab in the
brain (cfr next paragraph), and to the effects of particularly
damaging variants of molecules in specific brain
compartments (e.g. an increased Ab1–42:Ab1–40 ratio, occur-
rence of oxidized Ab.).
Furthermore, the major neuropathologic hallmarks of AD
such as amyloid plaques and NFTs display a distinctive
spatiotemporal distribution in the brain. The neurofibrillary
degeneration starts in the allocortex of the medial temporal
lobe, spreading to the associative isocortex and finally
affecting all isocortical areas, with the associative areas
being affected before and more severely than the primary
sensory, motor, and visual areas. In contrast to NFTs,
amyloid plaques accumulate mainly in the isocortex, with
the allocortex being affected to a lesser extent and later
than the associative isocortex. Among the isocortical areas,
as for NFTs, primary sensory, motor, and visual areas tend
to be less involved compared with association multimodal
areas [44]. This distinct temporal and regional distribution
of the neuropathologic hallmarks suggests a regional suscep-
tibility or vulnerability to the ongoing pathophysiological
processes. La Joie et al. (2012) evaluated concomitantly
Ab deposition, hypometabolism, and gray matter atrophy
in a brain region-specific manner in AD patients. They
demonstrated marked regional variability in the hierarchy
between these different brain alterations and speculated
that these reflect the differential involvement of region-
specific pathologic or protective mechanisms, such as the
presence of NFTs, disconnection, and compensation
Fig. 2. Ecosystem management principles may be useful to develop more effective AD therapies. (A) Shallow lakes can typically occur in one, two, or more
different equilibrium states: a clear state with submerged macrophytes or a turbid state dominated by phytoplankton. Both states are characterized by major
biotic differences, some of which stabilize the system in the respective state, with resilience to impacts. If the limiting nutrient (e.g. P, N) load of the lake exceeds
a critical value, eutrophication may cause a switch from the clear state to the turbid state that is generally considered as undesirable because plant communities
and rich fish fauna disappear and biodiversity decreases. In many cases, nutrient reduction, i.e. decreasing the nutrient load, is an insufficient measure to restore a
nonvegetated turbid lake to a clear vegetated state. Additional measures are required for restoration, such as food Web management, i.e. removal/alteration of a
part of the fish stock (biomanipulation), alteration of the water level, and sediment removal. Various models have been designed that simulate the behavior of
shallow lakes and can be useful for ecosystem management, as they indicate which measures are required to improve lake transparency [36]. (B) Ab immu-
notherapy has not yet proven successful in the treatment of AD. Anti-amyloid treatment only after dementia develops may be too little and too late to affect
the clinical course of the disease. Similar to successful ecosystem management, multiple measures that target various disease pathways may be required to
prevent or remediate AD. Abbreviations: AD, Alzheimer’s disease; Ab, amyloid-beta.
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amyloid accumulation followed by hypometabolism and at-
rophy were also observed in a study on autosomal dominant
AD [46]. Despite the presence of amyloid deposition, it im-
pacts the metabolism and/or atrophy differently, depending
on its spatiotemporal pattern that is also related to cognitive
performance [47].
Similarly, spatial heterogeneity and associated variation
in the exchange of energy, species, and genotypes among
habitat patches or among ecosystem subcompartments are
also central to the functioning of ecosystems [48]. The
impact of spatial or temporal environmental heterogeneity
in an ecosystem can be illustrated by the example of eutro-
phication of a shallow lake (Fig. 2). Typically, the nutrient
enrichment will promote algal growth that leads to increased
water turbidity. With the reduced light penetration, sub-
merged macrophyte growth and photosynthesis are reduced,
which can result in a lower oxygen level in the water. Algal
biomass can sediment and promote bacterial growth at the
bottom of the lake, reducing the oxygen levels even more.Ultimately, this creates conditions stressful or even lethal
for aquatic invertebrates and fish. Therefore, the patterns
that occur during eutrophication can be considered as
unfavorable to the biota.
Finally, an asymptomatic (preprodromal) phase in AD
takes place whereby the first pathologic events occur
without affecting the cognitive ability of the patient. At a
critical point in time (threshold), a conversion takes place
to mild cognitive impairment (MCI) and later to AD. In
ecosystems, there is evidence that thresholds also occur
and have important effects on ecosystem services [49].
An ecological threshold is the point where abrupt changes
in an ecosystem property or small changes in an
environmental driver produce large responses in the
ecosystem. It has been suggested that ecosystems can exist
in alternative stable states [50] but given enough distur-
bance can be pushed over the hill (i.e. threshold) to another
state. Pushing back to the original state in ecosystems may
require going well beyond the threshold that initiated the
state transition (i.e. hysteresis).
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therapy design
In the past decades, significant progress has been made
in understanding AD mechanisms. However, numerous
clinical trials have not yet resulted in an effective AD
treatment. So far, our thinking has been dominated by a
linear cascade of molecular events that ultimately lead to
neurodegeneration in AD. The currently available
conventional therapies modulate biological processes
through a single molecular target, whereas the complex
and multifactorial nature of AD most likely calls for a
multitarget therapeutic solution. For example, the “Ab sys-
tem” alone is already far more complex than only the
prominent influence of Ab1–42, as subtle fluctuations of
Ab alloforms influence the trajectories through which olig-
omer toxicity manifests itself [23,24]. The structural
aspects and time frame of existence of Ab aggregated
states are influenced by multiple variables, as opposed to
a simple linear relationship. In this regard, network
medicine has been suggested to offer a platform for
studying both disease complexity (identifying disease
factors and pathways) and the interdependencies between
the different players [51]. Multitarget drugs are being
developed that target various key components in AD [52]
and future research and implementation of these
compounds in clinical trials will reveal their potential
success in the fight against AD.
We have highlighted here that for instance the behavior of
Ab in the context of AD shows many similarities with the
complexity of ecosystems (Fig. 1). Other disease-
contributing factors that add an extra level of complexity
have been deliberately omitted from this comparison, but
obviously they need to be taken into account in the future.
We want to raise the awareness that ecosystem management
principles may hold potential to pave the way for new
insights into the neurobiological disease mechanisms and
AD remediation/prevention.
A number of ecosystem management principles and
paradigms may be useful to develop novel AD therapies.
Promising paradigms include the notion that complex
systems can exist in alternative stable states, stabilized
by feedback mechanisms, and the fact that management
can stimulate to reach certain favorable equilibria
(Fig. 2). Additional information about temporal dynamics
and alternative trajectories in complex systems can be
generated by models. For instance, age-structured
population models [53] developed in ecology may help
to understand the evolution of molecules during the
course of AD development and how this process can be
influenced by changing environmental conditions. Time
series data combined with trials that alternate the order
of treatments/introduction of interactors in a complex
system can help to assess to what extent history matters
in determining the deterministic outcome of species or
molecule interactions [54].Moreover, all risk factors of AD that potentially can be
modified should be identified simultaneously, so
interventions can take place before the pathologic burden
and neurodegeneration are irreversible (e.g. before pro-
longed synaptic dysfunction or accumulated cell death).
In ecosystems, early warning signs for regime shifts pro-
vide a tool for the improvement of ecosystem manage-
ment and serve as an indicator for the implementation
of preventive actions to avoid undesirable transitions in
ecosystems [55,56]. For example, microbial-based moni-
toring programs have been applied in the Neuse River
Estuary in the United States to formulate and validate
water quality models aimed at predicting nutrient
productivity and algal bloom thresholds. In this context,
there are indications that an impending regime shift is
often announced by rapid fluctuations between the current
state and a potential future stable state (flickering). For
instance, clear water lakes may first become turbid for
brief periods of time before they shift to a permanent
turbid state [57]. Likewise, early warning signals can be
predictive for transitions in type II diabetes [58] and
clinical depression [59], which are clinical conditions
that can be associated with AD. We need to identify
thresholds and investigate the flickering of AD bio-
markers in time-lapse (or so-called longitudinal) experi-
ments (relatively well studied in autosomal dominant
familial AD). The currently used cerebrospinal fluid
(CSF) biomarkers reflect the core pathologic features of
AD and include total tau, phosphorylated tau, and Ab1–
42 [60]. Since the pathologic processes of AD can start
even decades before the first symptoms appear, these bio-
markers may provide means of early disease detection or
identification of the risk for developing AD. In addition,
biomarkers might prove valuable in monitoring the phar-
macodynamics effect of anti-AD drugs [61]. In this way,
the biochemical trajectories via which the disease mani-
fests itself could be monitored, and controlled interven-
tions can be made possible. This strategy is similar to
how ecosystem management has been successfully
applied in e.g. shallow lake restoration, where the status
and nutrient loading of the lake is continuously monitored
[36]. Although originally ecosystem management was
mostly based on trial-and-error, it developed into an
adaptive management (not only to change the system
but also to learn about the system) by an in-depth
monitoring of the system.4. Conclusion
In summary, we would like to stimulate a novel way to
approach AD and propose that combining network medicine
with general ecosystem management principles could be a
new and holistic approach to better understand AD pathol-
ogy and design successful therapies. In-depth studies by
combining the expertise of both researchers in the AD field
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of this ecosystem-based approach and its translation into
concrete solutions in the future. In addition to the potential
of our proposed approach to the AD field, we hypothesize
that this may also impact treatment perspectives of other
multifactorial neurodegenerative diseases, such as Parkin-
son’s disease.4.1. Recommendations and future perspectives
1. Because ecosystem management relies on the
analysis of relationships between various elements in
an ecosystem, lessons learned from successful
ecosystem management could be applied with the
aim to prevent or remediate AD. Similar to the com-
bined set of measures necessary for the successful
restoration of shallow lakes (Fig. 2A), remediation/
prevention of AD may require interventions at the
level of multiple disease pathways and components
(Fig. 2B). For example, a recent study describes the
design of a small molecule compound that targets
and modulates various pathologic facets of AD, by
integrating elements for Ab aggregation control, metal
chelation, reactive oxygen species regulation, and
antioxidant activity [62]. This work can be an impor-
tant step toward multitarget AD treatment, and clinical
testing of this and other compounds will reveal their
efficacy in the future. However, medication alone
might not be sufficient and needs to be complemented
with nonpharmacologic measures to constitute a holis-
tic and more effective disease management strategy.
Certain strategies have been shown to positively influ-
ence synaptic plasticity, such as increased fitness level
through physical exercise, cognitive training or mental
jogging, mindfulness, and dietary recommendations
(Fig. 2B).
2. The diagnostic guidelines of AD have recently been
updated to include CSF biomarkers. Biomarkers,
however, cannot only be used for early detection of
disease development and tracking of disease progres-
sion but also hold promise for more effective thera-
peutic interventions before AD progress is
irreversible. Similarly to flickering in ecosystems
(temporal fluctuations indicating the approach of a
threshold), studies must be conducted to determine
whether biomarkers also flicker, thereby announcing
the conversion of for instance MCI to AD. However,
this would require a more intensified monitoring and
biomarker profiling of patients, not via a yearly
investigation but more frequently. In conjunction
with other disease progression indices (e.g. Braak
staging), detailed biomarker information could then
reveal particular trajectories of disease progression,
thereby providing more insight into the heterogeneity
of AD and allowing for disease subtyping. Ulti-mately, the use of biomarkers might allow for inter-
ventions tailored to the individual (i.e. personalized
medicine) [61]. CSF biomarkers and pharmacody-
namic markers as well as genetic markers (e.g.
APOE genotyping) and pharmacogenomics are
already fully included in innovative early phase clin-
ical trials evaluating experimental drugs based on the
amyloid cascade hypothesis. The development of
behavioral (prevention) studies for cognitive decline
will be of high added value for the integrated
approach for supporting patients and their relatives
with drugs, assisted-living tools, and real-time moni-
toring [63].
3. The approach presented here can also facilitate
communication between different persons involved
in the AD field, i.e. researchers, medical doctors, care-
givers, and patients, as it offers a more convenient and
tangible way to illustrate, understand, and discuss the
biomolecular phenomena that occur in the brain. The
ecosystem paradigm might be a powerful means to
visually explain molecular aspects that occur in AD
during an expert consultation. To achieve this, all peo-
ple involved should be encouraged to translate the cur-
rent know-how on neurobiological phenomena and
AD (management) to ecosystem observations (and
vice versa).
4. An interdisciplinary scientific effort focusing on
treatment development, in which researchers, medi-
cal experts, and caregivers gather to reflect on the dis-
ease, is required for a deeper understanding of the
underlying neurobiology of AD. The ecosystem
paradigm may stimulate cross-disciplinary thinking
and lead to effective dementia prevention approaches
that hitherto have not yet been considered. This
might lead to the development of a set of practical
guidelines to be recommended to all persons
involved and in particular to patients and caregivers.
5. An evaluation is required to what extent our claim
holds true for all aspects of disease and ecosystem
management, not to overlook potential fundamental
differences, and whether other analogies may provide
deeper insight. For example, contrary to species, mol-
ecules (such as Ab) are typically not self-replicating
entities. Their dynamics and turnover are determined
by the surrounding tissue that produces them, rather
than by differential reproductive success, migration,
and mortality, as would be the case for species in an
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1. Systematic review: The authorship is multidisci-
plinary, consisting of biophysicists and experts in
ecology and clinical neurology, using, from their
respective expertise, traditional sources to review
literature. We explore the parallels between the
complexity of the molecular interactions within Alz-
heimer’s disease (AD) and the complex architecture
of ecosystems. Relevant literature has been appropri-
ately cited.
2. Interpretation: By highlighting some commonalities
between AD and concepts of ecosystem manage-
ment, we propose that combining network medicine
with general ecosystemmanagement principles could
be a new and holistic approach to understand AD pa-
thology and design novel therapies. Our approach
also offers an interesting communication tool.
3. Future directions: The development of behavioral
studies for cognitive decline and the identification
of earlywarning signals can help to predict transitions
in the course of AD development. This will be of high
added value for the integrated approach for support-
ing patients and their relatives using drugs, assisted-
living tools, and real-time monitoring.References
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Glossary box
Amyloid-beta (Ab) peptide: aw4 kDa monomeric poly-
peptide that has a strong tendency to self-aggregate into olig-
omers and fibrils. The Ab peptide is the main constituent of
one of the main pathologic hallmarks of AD, the amyloid
plaques, and plays a primary role in AD development and
pathology.
Ecosystem: a dynamic and complex system comprising
plant, animal, and microorganism communities with their
nonliving environment interacting as a functional unit
(defined here following [64]).
Ecosystem service: an activity or function of an
ecosystem that provides benefit to humans (defined here
following [64]).
Epigenetics: the acquired and heritable modifications on
DNA that regulate the expression and functions of genes
without affecting the DNA nucleotide sequence, including
DNA (hydroxyl)methylation and histone modifications
(defined here following [33]). Epigenetic changes are
considered as a mechanism by which the environment can
interact with the genome.
Eutrophication: the natural or artificial increase in
nutrient load in an ecosystem and the effects of this increase
on the ecosystem.
Network medicine: an integrated study of genomics, tran-
scriptomics, proteomics, metabolomics, phenomics, and
environmental perturbations, such as pharmacologic inter-
vention or pathogenic infection, for the purpose of under-
standing human disease and how to cure it [51].
Patch: a relatively homogeneous subunit of an ecosystem
or a spatially defined unit delineating a single ecosystem (e.g.
a lake). Some ecosystems can be viewed as a mosaic of
different patches, illustrating their spatial heterogeneity.
Other ecosystems exist as discrete patches that may interact
with the surrounding landscape matrix as well as with distant
patches via dispersal and exchange of energy andmatter [48].
Priority effect: this phenomenon occurs when species
that arrive first in a community significantly affect the
establishment, growth, or reproduction of species arriving
later and thus affect community functioning. The future
development of the community may thus depend on its
past recruitment history and on the persistence of estab-
lished residents [11].
Productivity: rate of conversion of resources into
biomass, usually expressed in units of mass per unit area
(volume) per unit time.
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